New Addition to Covered Stock: OPT (OPTHEA)
Opthea Limited (ASX:OPT), a late stage
biopharmaceutical company developing first-in-class novel biologic therapies to treat back-of-the eye
diseases namely wet AMD which is a leading cause of blindness in people aged >55 years and DME the leading cause of blindness
amongst diabetics. There are already existing treatment for these two leading causes of blindness via drugs Lucentis (Roche/Novartis) and
Eyelea (Regeneron / Bayer) in a market that generated $9.2B in 2017. Opthea's lead drug development candidate OPT-302 is designed to
add-on and accentuate these existing remedies, not compete by offering a novel and differentiated additional treatment to VEGF-C and VEGF-D while Lucentis and Eyelea only addresses VEGF-A- VEGF represent vascular endothelial growth factor responsible for vessel growth and vascular leakages. The potential market opportunity presented by OPT-302 is estimated to be in excess of $10B.
OPT is now trading at just $150m market cap and has received positive safety review from its Phase 2b clinical trials.
COVERAGE DATE STOCKS PRICE ON COVERAGE DATE PRICE @ARVO GAIN% 17/10 OPT $ 0.600 $ 0.600 0.0% 15/10 PPS $ 0.915 $ 0.885 -3.3% 15/10 SVA $ 0.033 $ 0.031 -6.1% 15/10 APX $ 12.010 $ 11.860 -1.2% 15/10 PME $ 9.990 $ 10.160 1.7% 11/10-close PPS $ 0.925 $ 0.970 4.9% 11/10-close BBUS $ 4.750 $ 4.810 1.3% 3/10 BIT $ 0.140 $ 0.275 96.4% 26/9-close CXL $ 0.735 $ 0.800 8.8% 20/9-close 4DS $ 0.064 $ 0.066 3.1% 3/9 NST $ 8.140 $ 8.965 10.1% 29/8-close SVA $ 0.037 $ 0.035 -5.4% 20/8-close NGI $ 5.810 $ 5.160 -11.2% 8/8-close SFC $ 15.050 $ 16.470 9.4% 6/8-close CGL $ 7.080 $ 7.930 12.0% 31/7-close MYE $ 1.180 $ 1.435 21.6% 30/7-close MP1 $ 4.370 $ 3.990 -8.7% 26/7-close SKF $ 0.150 $ 0.200 33.3% 24/7-close ZEN $ 1.060 $ 0.785 -25.9% 23/7-close CXL $ 0.630 $ 0.830 31.7% 17/7 COE $ 0.445 $ 0.470 5.6% 13/7-close SHL $ 26.500 $ 25.360 -4.3% 29/6 BYE $ 0.340 $ 0.285 -16.2% 28/6-close ATC $ 0.195 $ 0.140 -28.2% 18/6-close A2M $ 10.780 $ 11.490 6.6% 18/6-close CGC $ 8.750 $ 7.240 -17.3% 14/6-close NZK $ 2.240 $ 2.480 10.7% 4/6-close BUB $ 0.830 $ 0.625 -24.7% 15/5-close SW1 $ 0.410 $ 0.380 -7.3% 14/5-close RHC $ 65.420 $ 55.250 -15.5% 9/5-close FYI $ 0.145 $ 0.115 -20.7% 3/5-close 4DS $ 0.057 $ 0.100 75.4% 2/5-close PME $ 8.150 $ 10.860 33.3% 1/5-close TTT $ 1.540 $ 1.525 -1.0% 30/4-close CTD $ 24.880 $ 33.540 34.8% 18/4-close CLV $ 1.030 $ 1.575 52.9% 18/4-close VIV $ 0.054 $ 0.043 -20.4% 11/4-close APX $ 8.820 $ 15.010 70.2% 11/4-close BHP $ 29.440 $ 32.385 10.0% 11/4-close PPS $ 0.595 $ 1.135 90.8% 11/4-close PTB $ 0.545 $ 0.625 14.7% Return @ 10.83% assuming @ $1k even per stock
Opthea’s lead drug development
candidate OPT‑302, blocks the
activity of two members of this
family, namely VEGF-C and VEGF-D.
Approved therapies for wet AMD and
DME include Lucentis® (ranibizumab)
and Eylea® (aflibercept). These
agents block the activity of VEGF-A,
but not VEGF-C or VEGF-D.
- Forums
- ASX - General
- Its Over
Its Over, page-360
-
- There are more pages in this discussion • 22,023 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Featured News
The Watchlist
CC9
CHARIOT CORPORATION LTD
Shanthar Pathmanathan, MD
Shanthar Pathmanathan
MD
Previous Video
Next Video
SPONSORED BY The Market Online